Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Blood 2016 Jan 20;127(2):208-15. Epub 2015 Oct 20.

Department I for Internal Medicine and Center of Integrated Oncology, University of Cologne, Cologne, Germany; Cluster of Excellence Cellular Stress Responses in Aging Associated Diseases, University of Cologne, Cologne, Germany.

Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine, cyclophosphamide (FC), and rituximab (R) remains the standard therapy for fit patients with untreated chronic lymphocytic leukemia (CLL). Herein, we present the long-term follow-up of the randomized CLL8 trial reporting safety and efficacy of FC and FCR treatment of 817 treatment-naïve patients with CLL. The primary end point was progression-free survival (PFS). With a median follow-up of 5.9 years, median PFS were 56.8 and 32.9 months for the FCR and FC group (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.50-0.69, P < .001). Median overall survival (OS) was not reached for the FCR group and was 86.0 months for the FC group (HR, 0.68; 95% CI, 0.54-0.89, P = .001). In patients with mutated IGHV (IGHV MUT), FCR improved PFS and OS compared with FC (PFS: HR, 0.47; 95% CI, 0.33-0.68, P < .001; OS: HR, 0.62; 95% CI, 0.34-1.11, P = .1). This improvement remained applicable for all cytogenetic subgroups other than del(17p). Long-term safety analyses showed that FCR had a higher rate of prolonged neutropenia during the first year after treatment (16.6% vs 8.8%; P = .007). Secondary malignancies including Richter's transformation occurred in 13.1% in the FCR group and in 17.4% in the FC group (P = .1). First-line chemoimmunotherapy with FCR induces long-term remissions and highly relevant improvement in OS in specific genetic subgroups of fit patients with CLL, in particular those with IGHV MUT. This trial was registered at www.clinicaltrials.gov as #NCT00281918.

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-06-651125DOI Listing
January 2016
115 Reads

Publication Analysis

Top Keywords

patients cll
12
fcr group
12
long-term remissions
8
fit patients
8
cll8 trial
8
ighv mut
8
fcr
8
patients
5
group
5
improved pfs
4
pfs compared
4
patients mutated
4
001 patients
4
mut fcr
4
ighv ighv
4
mutated ighv
4
compared pfs
4
fcr improved
4
95% 033-068
4
95% 034-111
4

References

(Supplied by CrossRef)
Allotransplantation for chronic lymphocytic leukemia.
Dreger et al.
Hematology Am Soc Hematol Educ Program 2009

Similar Publications